{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T13:08:51Z","timestamp":1793279331233,"version":"4.5.0"},"reference-count":41,"publisher":"Academy of Managed Care Pharmacy","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMCP"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.18553\/jmcp.2026.32.3.281","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T03:23:21Z","timestamp":1772249001000},"page":"281-291","source":"Crossref","is-referenced-by-count":7,"title":["Trends in 1-year persistence and adherence among initiators of high-potency, weight loss\u2013indicated glucagon-like peptide 1 receptor agonists"],"prefix":"10.18553","volume":"32","author":[{"given":"Landon Z.","family":"Marshall","sequence":"first","affiliation":[{"name":"Prime Therapeutics, LLC, Eagan, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick P.","family":"Gleason","sequence":"additional","affiliation":[{"name":"Prime Therapeutics, LLC, Eagan, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Friedlander","sequence":"additional","affiliation":[{"name":"Prime Therapeutics, LLC, Eagan, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Farley","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care & Health Systems, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin Y.","family":"Urick","sequence":"additional","affiliation":[{"name":"Prime Therapeutics, LLC, Eagan, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7818","reference":[{"key":"r1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2011.08.005"},{"key":"r2","doi-asserted-by":"publisher","DOI":"10.3390\/nu14204253"},{"key":"r3","unstructured":"U.S. Centers for Disease Control and Prevention. About obesity. Published January 23, 2024. Accessed August 7, 2025. https:\/\/www.cdc.gov\/obesity\/php\/about\/index.html"},{"key":"r4","unstructured":"Lopez C, Bendix J, Sagynbekov K. Weighing down America: 2020 update. Milliken Institute. Published 2020. Accessed August 8, 2025. https:\/\/milkeninstitute.org\/sites\/default\/files\/reports-pdf\/Weighing%20Down%20America%20v12.3.20_0.pdf"},{"key":"r5","unstructured":"Center for Drug Evaluation and Research. Approval package for: Wegovy injection (semaglutide). US Food and Drug Administration. Published June 2021. Accessed August 7, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/215256Orig1s000Approv.pdf"},{"key":"r6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"r7","unstructured":"Center for Drug Evaluation and Research. Approval package for: Zepbound injection (tirzepatide). US Food and Drug Administration. Published November 2023. Accessed August 7, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/217806Orig1s000Approv.pdf"},{"key":"r8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2023.10.002"},{"key":"r10","doi-asserted-by":"publisher","DOI":"10.7326\/M24-0019"},{"key":"r11","unstructured":"US Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Published April 28, 2025. Accessed August 7, 2025. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize"},{"key":"r12","doi-asserted-by":"publisher","DOI":"10.2337\/cd23-0023"},{"key":"r13","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.5015"},{"key":"r14","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2024.23332"},{"key":"r15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.13172"},{"key":"r16","doi-asserted-by":"publisher","DOI":"10.2337\/db25-786-P"},{"key":"r17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.57349"},{"key":"r18","unstructured":"Blue Health Intelligence. Real-world trends in GLP-1 treatment persistence and prescribing for weight management. Blue Cross Blue Shield Association. Accessed August 7, 2025. https:\/\/www.bcbs.com\/media\/pdf\/BHI_Issue_Brief_GLP1_Trends.pdf"},{"key":"r19","doi-asserted-by":"publisher","DOI":"10.1002\/oby.24315"},{"key":"r20","unstructured":"United Healthcare and Health Action Council. The obesity epidemic: Growing health impacts and cost implications. Accessed August 11, 2025. https:\/\/healthactioncouncil.org\/media\/i5qj3qah\/2025-hac-white-paper.pdf"},{"key":"r21","unstructured":"Williams E, Rudowitz R, Bell C. Medicaid coverage of and spending on GLP-1s. Kaiser Family Foundation. Published November 4, 2024. Accessed August 4, 2025. https:\/\/www.kff.org\/medicaid\/issue-brief\/medicaid-coverage-of-and-spending-on-glp-1s\/"},{"key":"r22","unstructured":"Plier R. GLP-1 drugs responsible for over ten percent of annual claims. International Foundation of Employee Benefit Plans. Published May 22, 2025. Accessed August 4, 2025. https:\/\/www.ifebp.org\/resources-news\/news-and-regulatory-updates\/press-room\/press-releases\/2025\/05\/22\/glp-1-drugs-responsible-for-over-ten-percent-of-annual-claims"},{"key":"r23","unstructured":"Prime Therapeutics. Real-world analysis of GLP-1a drugs for weight loss finds low adherence and increased cost in first year. Published July 11, 2023. Accessed October 1, 2025. https:\/\/www.primetherapeutics.com\/w\/real-world-analysis-of-glp-1a-drugs-for-weight-loss-finds-low-adherence-and-increased-cost-in-first-year"},{"key":"r24","unstructured":"Kaiser Family Foundation. Annual family premiums for employer coverage rise 7% to average $25,572 in 2024, benchmark survey finds, after also rising 7% last year. Published October 9, 2024. Accessed August 4, 2025. https:\/\/www.kff.org\/health-costs\/press-release\/annual-family-premiums-for-employer-coverage-rise-7-to-average-25572-in-2024-benchmark-survey-finds-after-also-rising-7-last-year\/"},{"key":"r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103680"},{"key":"r26","author":"Horn DB","journal-title":"JAMA Intern Med"},{"key":"r27","author":"Celletti F","year":"2025","journal-title":"JAMA. Published"},{"key":"r28","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.5586"},{"key":"r29","doi-asserted-by":"crossref","unstructured":"Pearson SD, Whaley CM, Emond SK. Affordable access to GLP-1 obesity medications: Strategies to guide market action and policy solutions. Institute for Clinical and Economic Review. Published April 9, 2025. Accessed August 6, 2025. https:\/\/icer.org\/wp-content\/uploads\/2025\/04\/Affordable-Access-to-GLP-1-Obesity-Medications-_-ICER-White-Paper-_-04.09.2025.pdf","DOI":"10.57264\/cer-2025-0083"},{"key":"r30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"r31","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14512"},{"key":"r32","unstructured":"Centers for Medicare & Medicaid Services. Medicare 2025 Part C & D Star ratings technical notes. Updated October 3, 2024. Accessed October 8, 2025. https:\/\/www.cms.gov\/files\/document\/2025-star-ratings-technical-notes.pdf"},{"issue":"4","key":"r33","first-page":"188","volume":"12","author":"Glasheen WP","year":"2019","journal-title":"Am Health Drug Benefits"},{"key":"r34","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"r35","unstructured":"Congressional Budget Office. How would authorizing Medicare to cover anti-obesity medications affect the federal budget? October 8, 2024. Accessed August 6, 2025. https:\/\/www.cbo.gov\/publication\/60441"},{"key":"r36","doi-asserted-by":"publisher","DOI":"10.1159\/000546472"},{"key":"r37","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010145"},{"issue":"4","key":"r38","first-page":"340","volume":"110","author":"Rao M","year":"2024","journal-title":"Am Fam Physician"},{"key":"r39","doi-asserted-by":"publisher","DOI":"10.1002\/oby.24336"},{"key":"r40","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.22284"},{"key":"r41","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-2575"}],"container-title":["Journal of Managed Care & Specialty Pharmacy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T03:24:00Z","timestamp":1772681040000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jmcp.org\/doi\/10.18553\/jmcp.2026.32.3.281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.18553\/jmcp.2026.32.3.281"],"URL":"https:\/\/doi.org\/10.18553\/jmcp.2026.32.3.281","relation":{},"ISSN":["2376-0540","2376-1032"],"issn-type":[{"value":"2376-0540","type":"print"},{"value":"2376-1032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}